A Randomized Trial of Topical Fibrinogen-Depleted Human Platelet Lysate Treatment of Dry Eye Secondary to Chronic Graft-versus-Host Disease

Sugar, Alan; Shtein, Roni M.; Soong, H. Kaz; Hussain, Munira; Chamberlain, Winston; Nanji, Afshan; Clements, John D.; Maykovski, Jennifer; Labadzinzki, Paula Cisternas; Dana, Reza; Jia, Junbo; Ciolino, Joseph B.; Caccaviello, John; Kelly, D. Patrick; Habibi, Roya; Ta, Christopher N.; Yu, Charles; Lin, Charles P.; Hirabayashi, Kristin E.; Ureña, Gabriel Valerio; Kawale, Supriya; Nunez, Mariana; Irvine, John A.; Lee, Olivia; Chu, Matthew L. H.; Daluvoy, Melissa; Pérez, Víctor L.; Balajonda, Elmer; Hawks, Terry; Olson, Joshua; Maltry, Amanda C.; Hou, Joshua H.; Elasky, Wendy; Jhanji, Vishal; Aubourg, Rose Carla; Stulting, R. Doyle; Waller, Edmund K.; Jagirdar, Neera; Walts, Terence

doi:10.1016/j.xops.2022.100176

Cited by 6 publications

(3 citation statements)

References 23 publications

(37 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another US study evaluated 306 individuals post‐HSCT with oGVHD (acute/chronic not specified) and found other symptoms (not previously mentioned) present including burning/stinging in 59% ( n = 181), vision changes in 53% ( n = 162), pain in 52% ( n = 159), and wind sensitivity in 46% ( n = 141) 69 . One American study also found that sensations of grittiness were reported by 42% of individuals with coGVHD 70 . Therefore, further investigation is warranted to distinguish the symptom profile in aoGVHD versus coGVHD.…”

Section: Symptoms Of Ogvhd Versus Dedmentioning

confidence: 98%

See 1 more Smart Citation

How does ocular graft‐versus‐host disease fit under the dry eye umbrella? A review

Kantor,

Tovar,

Wang

et al. 2024

Clinical Exper Ophthalmology

View full text Add to dashboard Cite

Graft‐versus‐host disease (GVHD) is a systemic disease that can affect multiple organs as a consequence of an allogeneic haematopoietic stem cell transplant. One organ system that is often affected in GVHD is the eyes. Ocular GVHD (oGVHD) may involve various structures within the eye including the lacrimal glands, eyelids, conjunctiva, cornea, and nasolacrimal ducts, and is a source of morbidity in patients with GVHD. Common presenting features of GVHD overlap with dry eye disease (DED), including decreased tear production, epithelial disruption, and Meibomian gland dysfunction (MGD). In this review, we aim to compare oGVHD and DED to better understand the similarities and differences between the conditions, with a focus on pathophysiology, risk factors, clinical features, and treatments.

show abstract

Section: Symptoms Of Ogvhd Versus Dedmentioning

confidence: 98%

“…69 One American study also found that sensations of grittiness were reported by 42% of individuals with coGVHD. 70 Therefore, further investigation is warranted to distinguish the symptom profile in aoGVHD versus coGVHD.…”

Section: Symptoms Of Ogvhd Versus Dedmentioning

confidence: 99%

How does ocular graft‐versus‐host disease fit under the dry eye umbrella? A review

Kantor,

Tovar,

Wang

et al. 2024

Clinical Exper Ophthalmology

View full text Add to dashboard Cite

show abstract

“…The products were compared to a control substance for 7 weeks in 64 patients. The new platelet lysate product was safe and well‐tolerated with an improvement in patient‐reported parameters although larger studies are needed to confirm these effects [60].…”

Section: New Developmentsmentioning

confidence: 99%

Eye drops of human origin—Current status and future needs: Report on the workshop organized by the ISBT Working Party for Cellular Therapies

et al. 2023

View full text Add to dashboard Cite

Background and Objectives Serum eye drops (SEDs) are used to treat ocular surface disease (OSD) and to promote ocular surface renewal. However, their use and production are not standardized, and several new forms of human eye drops have been developed. Materials and Methods The International Society for Blood Transfusion Working Party (ISBT WP) for Cellular Therapies held a workshop to review the current types of eye drops of human origin (EDHO) status and provide guidance. Results The ISBT WP for Cellular Therapies introduced the new terminology ‘EDHO’ to emphasize that these products are analogous to ‘medical products of human origin’. This concept encompasses their source (serum, platelet lysate, and cord blood) and the increasingly diverse spectrum of clinical usage in ophthalmology and the need for traceability. The workshop identified the wide variability in EDHO manufacturing, lack of harmonized quality and production standards, distribution issues, reimbursement schemes and regulations. EDHO use and efficacy is established for the treatment of OSD, especially for those refractory to conventional treatments. Conclusion Production and distribution of single‐donor donations are cumbersome and complex. The workshop participants agreed that allogeneic EDHO have advantages over autologous EDHO although more data on clinical efficacy and safety are needed. Allogeneic EDHOs enable more efficient production and, when pooled, can provide enhanced standardization for clinical consistency, provided optimal margin of virus safety is ensured. Newer products, including platelet‐lysate‐ and cord‐blood‐derived EDHO, show promise and benefits over SED, but their safety and efficacy are yet to be fully established. This workshop highlighted the need for harmonization of EDHO standards and guidelines.

show abstract

Understanding Ocular Graft-Versus-Host Disease to Facilitate an Integrated Multidisciplinary Approach

Surico,

Luo

2024

Transplantation and Cellular Therapy

View full text Add to dashboard Cite

A Randomized Trial of Topical Fibrinogen-Depleted Human Platelet Lysate Treatment of Dry Eye Secondary to Chronic Graft-versus-Host Disease

Cited by 6 publications

References 23 publications

How does ocular graft‐versus‐host disease fit under the dry eye umbrella? A review

How does ocular graft‐versus‐host disease fit under the dry eye umbrella? A review

Eye drops of human origin—Current status and future needs: Report on the workshop organized by the ISBT Working Party for Cellular Therapies

Understanding Ocular Graft-Versus-Host Disease to Facilitate an Integrated Multidisciplinary Approach

Contact Info

Product

Resources

About